Effect of phosphodiesterase type 5 inhibitors on prostate cancer
10.3760/cma.j.issn.1673-4203.2017.03.021
- VernacularTitle:5型磷酸二酯酶抑制剂对前列腺癌的影响
- Author:
Peng CHEN
;
Qiang WEI
- Keywords:
Phosphodiesterase type 5 inhibitor;
Prostatic neoplasms;
Erectile dysfunction;
Recurrence
- From:
International Journal of Surgery
2017;44(3):212-216
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction was one of the most frequently postoperative complications after radical prostatectomy,which has been deeply concentrated by patients and urologists,along with more and more people were diagnosed as localized prostate cancer.Widely being used for erectile dysfunction after radical prostatectomy,the efficacy and safety of phosphodiesterase type 5 inhibitors have been confirmed by many clinical studies.However,the influences of phosphodiesterase type 5 inhibitors on the occurrence and progression of cancer are still not completely revealed at present.Additionally,the efficiency of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomny is still controversial,though it has been demonstrated that phosphodiesterase type 5 inhibitors is not associated with the occunrence of prostate cancer based on recent clinical studies.We will review the possibly mechanisms of phosphodiesterase type 5 inhibitors in oncologic occurrence,especially in the occurrence of prostate cancer and its biochemical recurrence after radical prostatectomy.
